Newly diagnosed patients initiating romiplostim were older and had evidence of more severe thrombocytopenia than patients with persistent or chronic ITP.

In clinical practice, romiplostim was effective in raising platelet counts regardless of the duration of ITP, similar to previous clinical trials.

Adverse drug reactions were rare for patients with any ITP duration.